Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UMIN000001382 | Registry Identifier | UMIN-CTR | |
| JapicCTI-080590 | Registry Identifier | JapicCTI | |
| U1111-1118-4073 | Registry Identifier | WHO |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.
Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.
Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.
The present study was planned to evaluate the efficacy and safety of alogliptin as an add-on to pioglitazone in type 2 diabetic patients with uncontrolled blood glucose despite treatment with pioglitazone as well as diet and exercise therapies.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD | Experimental |
| |
| Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD | Experimental |
| |
| Pioglitazone (15mg or 30mg ) QD | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Alogliptin and pioglitazone | Drug | Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. | Baseline and Week 12. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (Week 2). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline. | Baseline and Week 2. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Professor, Diabetes and Endocrine Division, Department of Medicine | Kawasaki Medical School | Study Director |
Not provided
Participants with historical diagnosis of type 2 diabetes with uncontrolled blood glucose despite treatment with pioglitazone as well as diet and exercise therapies were enrolled in one of 3, once-daily (QD) treatment groups.
Participants enrolled at 33 investigative sites in Japan from 22 November 2007 to 22 October 2008.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD | Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
| FG001 | Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD | Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
| FG002 | Pioglitazone 15 mg or 30 mg QD | Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD | Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
| BG001 | Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 2). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 2. |
|
Treatment-emergent adverse events are any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug.
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD | Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bronchopneumonia | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| General Manager | Japan Development Center, Pharmaceutical Development Division | +81-6-6204-5257 | clinicaltrialregistry@tpna.com |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C520853 | alogliptin |
| D000077205 | Pioglitazone |
| ID | Term |
|---|---|
| D045162 | Thiazolidinediones |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Alogliptin and pioglitazone | Drug | Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
|
|
| Pioglitazone | Drug | Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
|
|
| Change From Baseline in Glycosylated Hemoglobin (Week 4). |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline. |
| Baseline and Week 4. |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. | Baseline and Week 8. |
| Change From Baseline in Fasting Plasma Glucose (Week 2). | The change between the value of fasting plasma glucose collected at week 2 and glycosylated hemoglobin collected at baseline. | Baseline and Week 2. |
| Change From Baseline in Fasting Plasma Glucose (Week 4). | The change between the value of fasting plasma glucose collected at week 4 and glycosylated hemoglobin collected at baseline. | Baseline and Week 4. |
| Change From Baseline in Fasting Plasma Glucose (Week 8). | The change between the value of fasting plasma glucose collected at week 8 and glycosylated hemoglobin collected at baseline. | Baseline and Week 8. |
| Change From Baseline in Fasting Plasma Glucose (Week 12). | The change between the value of fasting plasma glucose collected at week 12 or final visit and glycosylated hemoglobin collected at baseline. | Baseline and Week 12. |
| Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12). | The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and 2 hours after the start of the meal. | Baseline and Week 12. |
| Lack of Efficacy |
|
| Principal Investigator Discretion |
|
Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
| BG002 | Pioglitazone 15 mg or 30 mg QD | Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
| BG003 | Total | Total of all reporting groups |
| participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 |
| Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD |
Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
| OG002 | Pioglitazone 15 mg or 30 mg QD | Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. |
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 4). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 4. |
|
|
|
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (Week 8). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 8. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 2). | The change between the value of fasting plasma glucose collected at week 2 and glycosylated hemoglobin collected at baseline. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 2. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 4). | The change between the value of fasting plasma glucose collected at week 4 and glycosylated hemoglobin collected at baseline. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 4. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 8). | The change between the value of fasting plasma glucose collected at week 8 and glycosylated hemoglobin collected at baseline. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 8. |
|
|
|
|
| Secondary | Change From Baseline in Fasting Plasma Glucose (Week 12). | The change between the value of fasting plasma glucose collected at week 12 or final visit and glycosylated hemoglobin collected at baseline. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 12. |
|
|
|
|
| Secondary | Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12). | The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and 2 hours after the start of the meal. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | mg/dL | Baseline and Week 12. |
|
|
|
|
| Primary | Change From Baseline in Glycosylated Hemoglobin (Week 12). | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | Posted | Mean | Standard Deviation | percentage of Glycosylated Hemoglobin | Baseline and Week 12. |
|
|
|
|
| 1 |
| 111 |
| 5 |
| 111 |
| EG001 | Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD | Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. | 2 | 113 | 17 | 113 |
| EG002 | Pioglitazone 15 mg or 30 mg QD | Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks. | 5 | 115 | 13 | 115 |
| Nasopharyngitis | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
|
| Gallbladder cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Cerebral infarction | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Cataract | Eye disorders | MedDRA (11.1) | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Dental caries | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Blood creatine phosphokinase increased | Investigations | MedDRA (11.1) | Systematic Assessment |
|
The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.
| D001393 |
| Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| Mean Difference (Final Values) |
| -0.359 |
| 2-Sided |
| 95 |
| -0.432 |
| -0.287 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) |
| -0.635 |
| 2-Sided |
| 95 |
| -0.743 |
| -0.526 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) |
| -13.06 |
| 2-Sided |
| 95 |
| -17.86 |
| -8.26 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) |
| -14.82 |
| 2-Sided |
| 95 |
| -20.00 |
| -9.63 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) |
| -17.08 |
| 2-Sided |
| 95 |
| -22.64 |
| -11.53 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) |
| -16.49 |
| 2-Sided |
| 95 |
| -22.78 |
| -10.19 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) |
| -21.19 |
| 2-Sided |
| 95 |
| -30.43 |
| -11.95 |
| No |
| Superiority or Other |
| Mean Difference (Final Values) |
| -0.773 |
| 2-Sided |
| 95 |
| -0.913 |
| -0.634 |
| No |
| Superiority or Other |